WO2026017807 - COMPOSITIONS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2026/017807
Publication Date
22.01.2026
International Application No.
PCT/EP2025/070518
International Filing Date
17.07.2025
Title **
[English]
COMPOSITIONS AND USES THEREOF
[French]
COMPOSITIONS ET LEURS UTILISATIONS
Applicants **
BEECH BIOTECH SA
Inventors
COTTINGHAM, Ian
Priority Data
2410495.2
18.07.2024
GB
2503093.3
04.03.2025
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2929 | |
| EPO | Filing, Examination, Granting | 14345 | |
| Japan | Filing, Examination, Granting | 2392 | |
| South Korea | Filing, Examination, Granting | 2516 | |
| USA | Filing, Examination, Granting | 9190 |
Total:
31,372
Contact Us
Abstract[English]
An isolated polypeptide for use in medicine in a pregnant woman, wherein the polypeptide comprises a human variant IgG Fc domain having a mutation or combination of mutations with respect to the parent sequence which reduces binding of the Fc domain to any FcyR, and a mutation or combination of mutations with respect to the parent sequence which reduce binding of the Fc domain to FcRn, whereby matemofetal transfer is inhibited with respect to the parent sequence by at least 95% or more, wherein the isolated polypeptide binds endoglin, as well as methods of treatment using the same and compositions of matter compositions encoding or comprising the same.[French]
L'invention concerne un polypeptide isolé destiné à être utilisé en médecine chez une femme enceinte, le polypeptide comprenant un domaine Fc d'IgG variant humain ayant une mutation ou une combinaison de mutations par rapport à la séquence parente qui réduit la liaison du domaine Fc à n'importe quel FcyR, et une mutation ou une combinaison de mutations par rapport à la séquence parente qui réduisent la liaison du domaine Fc au FcRn, le transfert fœto-maternel étant inhibé par rapport à la séquence parente d'au moins 95% ou plus, le polypeptide isolé se liant à l'endogline, ainsi que des méthodes de traitement l'utilisant et des compositions de matière codant pour ou le comprenant.